The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of February) and will feature more than 12 hours of high-level keynotes and panel discussions.
Forbion's Tim Lohoff, Ph.D., Senior Associate, Forbion will co-chair the New Modalities Panel: The Future of Gene Editing together with Victoria English, Co-Founder & Editor of Evernow Publishing Ltd, publisher, MedNous (Evernow Publishing Ltd)
Panellists
Albert Seymour, President & CEO, Seamless Therapeutics, Inc.
Avencia Sanchez-Mejias PhD, Co-Founder & CEO, Integra Therapeutics
Monika Paule, Co-Founder, CEO & Board Member, Caszyme, LLC
Paul Vogel, Managing Director & VP of Research, AIRNA Corporation, Inc.
Sean Kendall, Partner, ARCH Venture Partners
This panel will delve into the advancements in gene editing technologies such as CRISPR, TALENs, and ZFNs, examining their impact on medical research and treatment options. Learn from pioneers in the field about the latest developments, ethical considerations, and the road ahead for gene therapies. You can view the agenda for the event below.
Day 1 (Wednesday, 26th of February)
Industry Roundtable
Investment Outlook for VC & PE in 2025 Panel
Next-Gen Platforms Panel: Opportunities for Investors
MedTech, Biotech, Digital, AI Panel: The Convergence
New Modalities Panel: The Future of Gene Editing
Advances in the Treatment of Neurological Disorders Panel
Day 2 (Thursday, 27th of February)
Pharma Dealmakers Panel
Greater China Biopharma Panel
Partnering in Oncology Panel
Cancer Progress Panel
Early-Stage Investment Panel
Rising Stars – Biotech Seed Companies Session
Click here for more information about this event.